|
Market Closed -
NYSE
16:00:00 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 2.690 USD | +3.07% |
|
+3.86% | +49.44% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 216.7 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 49.72% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 216.7 | 216.7 | 216.7 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 49.72% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 11.2x | 53.8x | 135x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.3x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 3.16x | 3.31x | 3.15x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.16x | 3.31x | 3.15x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 11.8x | -126x | 192x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 68.66 | 65.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 18.35 | -1.719 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.38 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.690 | 2.690 | 2.690 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 3/31/22 | 2/27/23 | 3/14/24 | 3/17/25 | 3/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 10.88x | - | - | - | 210M | |
| 41.24x | 13.94x | 30.97x | 0.48% | 1,255B | |
| 38.96x | 6.55x | 18.42x | 2.01% | 641B | |
| 36.79x | 8.37x | 17.26x | 2.42% | 505B | |
| 21.08x | 5.12x | 12.75x | 2.56% | 381B | |
| 95.75x | 5.88x | 25.02x | 2.35% | 357B | |
| 22.88x | 5.88x | 14.19x | 2.73% | 303B | |
| 24.26x | 4.85x | 13.68x | 1.8% | 286B | |
| 29.25x | 7.46x | 13.36x | 2.19% | 249B | |
| -40.09x | 7.32x | 45.96x | 1.97% | 208B | |
| Average | 28.10x | 7.26x | 21.29x | 2.06% | 418.54B | |
| Weighted average by Cap. | 35.93x | 8.73x | 22.53x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
